Veru Announces FDA Grant of Fast Track Designation for Enobosarm for the Treatment of AR+ ER+ HER2- Metastatic Breast Cancer
10 janv. 2022 08h30 HE
|
Veru Inc.
-- FDA Fast Track Designation is Intended to Expedite the Development and Review of New Drugs to Treat Serious Medical Conditions that Fill Unmet Medical Need -- -- Phase 3 ARTEST Registration Study...
Veru to Present Corporate Update at the H.C. Wainwright BioConnect Conference on January 10-13, 2022
03 janv. 2022 08h30 HE
|
Veru Inc.
MIAMI, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer,...
Veru Announces FDA Approval of ENTADFI, a New Treatment for Benign Prostatic Hyperplasia
13 déc. 2021 08h30 HE
|
Veru Inc.
--ENTADFI (Finasteride and Tadalafil) Capsules to Treat Benign Prostatic Hyperplasia-- --Commercialization Will Start Early Calendar Year 2022-- --ENTADFI to Be Marketed and Distributed by...
Veru Announces Presentation of Preclinical Evidence Supporting the Therapeutic Benefit of Enobosarm Alone or in Synergistic Combination with a CDK4/6 Inhibitor Against Palbociclib Resistant Metastatic Breast Cancer at the 2021 San Antonio Breast Cancer Symposium
08 déc. 2021 08h00 HE
|
Veru Inc.
MIAMI, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast cancer and prostate...
Veru Reports Record Fiscal 2021 Full-Year Financial Results
02 déc. 2021 06h30 HE
|
Veru Inc.
--FY21 Net Revenues Increase 44% to $61 Million and Gross Profit Increases 56% to $48 Million, Achieving New Historical Highs-- --Phase 3 Sabizabulin COVID-19 Clinical Study for Treatment of...
Veru to Report Fiscal 2021 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 2nd
18 nov. 2021 08h30 HE
|
Veru Inc.
MIAMI, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer,...
Veru Ranked as one of the Fastest-Growing Companies in North America on the 2021 Deloitte Technology Fast 500
18 nov. 2021 08h00 HE
|
Veru Inc.
-- Veru is a Late-Stage Clinical Development Biopharmaceutical Company Developing Drugs for the Treatment of Breast Cancer, Prostate Cancer, and COVID-19, Large Premium Global Markets– -- 212%...
Veru to Participate in Fireside Chat at the Jefferies London Healthcare Conference on November 16-18, 2021
08 nov. 2021 08h30 HE
|
Veru Inc.
MIAMI, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer,...
Veru Enrolls First Patient in International Phase 3 ARTEST Clinical Trial of Enobosarm in Metastatic Breast Cancer
13 oct. 2021 08h30 HE
|
Veru Inc.
-- Enobosarm is a novel targeted hormone drug to be evaluated in the 3rd line treatment of androgen receptor positive metastatic breast cancer -- -- A companion diagnostic test will be developed,...
Veru Announces Positive Updated Data from Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress
20 sept. 2021 08h30 HE
|
Veru Inc.
MIAMI, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer,...